Revance Therapeutics, Inc. Promotes Dustin Sjuts as President
November 09, 2021 at 04:15 pm EST
Share
Revance Therapeutics, Inc. announced that on November 9, 2021, the Board of Directors (the ?Board?) of the Company approved the promotion of Dustin Sjuts, the Company?s Chief Commercial Officer, Aesthetics & Therapeutics, to President, effective as of November 9, 2021 (the ?Effective Date?). In this role, Mr. Sjuts will report to Mark J. Foley, the Chief Executive Officer and principal executive officer of the Company. As President, Mr. Sjuts will oversee all Company operations excluding regulatory, technical operations and general and administrative functions. Mr. Sjuts, age 42, served as the Company?s Chief Commercial Officer, Aesthetics & Therapeutics from December 2019 to November 2021. Mr. Sjuts previously served as the Company?s Head of Commercial, Aesthetics and Therapeutics, from November 2018 to November 2019, and as Vice President, Strategy and Sales from March 2018 to November 2018. Prior to joining the Company, Mr. Sjuts held leadership positions at Nestle Skin Health, including Business Unit Head, China, from January 2017 to April 2018 and Senior Director of Marketing from February 2015 to December 2016. Previously, Mr. Sjuts held positions of increasing responsibility across a range of markets and disciplines with Alphaeon Corporation and Allergan plc, where he was responsible for creating and executing product adoption and sales growth strategies.
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.